Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: FLNB

Gene summary for FLNB

Gene summary.

Gene information	Species	Human
	Gene symbol	FLNB
	Gene ID	2317
	Gene name	filamin B
	Gene Alias	ABP-278
	Cytomap	3p14.3
	Gene Type	protein-coding
	GO ID	GO:0000902
	UniProtAcc	O75369

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2317	FLNB	P7	Human	Prostate	Tumor	3.22e-02	6.43e-01	-0.1025
2317	FLNB	P10	Human	Prostate	Tumor	4.48e-03	5.20e-01	-0.0902
2317	FLNB	GSM5353215_PA_AUG_PB_1B_S2	Human	Prostate	Tumor	1.46e-08	9.85e-01	0.1557
2317	FLNB	GSM5353216_PA_PB1A_Pool_1_3_S50_L002	Human	Prostate	Tumor	5.23e-04	6.80e-01	0.159
2317	FLNB	GSM5353217_PA_PB1A_Pool_2_S107_L004	Human	Prostate	Tumor	3.41e-04	9.59e-01	0.156
2317	FLNB	GSM5353221_PA_PB2A_Pool_1_3_S25_L001	Human	Prostate	Tumor	1.56e-12	7.54e-01	0.1633
2317	FLNB	GSM5353222_PA_PB2B_Pool_1_3_S52_L002	Human	Prostate	Tumor	5.41e-19	8.05e-01	0.1608
2317	FLNB	GSM5353223_PA_PB2B_Pool_2_S26_L001	Human	Prostate	Tumor	1.12e-17	9.23e-01	0.1604
2317	FLNB	GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001	Human	Prostate	Tumor	1.54e-10	7.13e-01	0.1621
2317	FLNB	GSM5353225_PA_PR5196-1_Pool_1_2_3_S53_L002	Human	Prostate	Tumor	8.45e-07	7.68e-01	0.1619
2317	FLNB	GSM5353226_PA_PR5196-2_Pool_1_2_3_S54_L002	Human	Prostate	Tumor	4.13e-04	7.67e-01	0.159
2317	FLNB	GSM5353227_PA_PR5199-193K_Pool_1_2_3_S55_L002	Human	Prostate	Tumor	6.41e-09	6.63e-01	0.1602
2317	FLNB	GSM5353232_PA_PR5249_T1_S3_L001	Human	Prostate	Tumor	1.64e-06	8.11e-01	0.1439
2317	FLNB	GSM5353236_PA_PR5251_T1_S7_L001	Human	Prostate	Tumor	2.98e-13	9.75e-01	0.1608
2317	FLNB	GSM5353237_PA_PR5251_T2_S8_L001	Human	Prostate	Tumor	1.91e-09	9.80e-01	0.1622
2317	FLNB	GSM5353240_PA_PR5254_T1_S15_L001	Human	Prostate	Tumor	4.49e-18	7.55e-01	0.1575
2317	FLNB	GSM5353243_PA_PR5261_T1_S23_L002	Human	Prostate	Tumor	1.23e-14	6.31e-01	0.1545
2317	FLNB	GSM5353244_PA_PR5261_T2_S24_L002	Human	Prostate	Tumor	2.61e-14	7.23e-01	0.1569
2317	FLNB	GSM5353248_PA_PR5269_4_S28_L002	Human	Prostate	Tumor	1.55e-05	7.41e-01	0.1541
2317	FLNB	P1_S1_AK	Human	Skin	AK	5.45e-19	5.19e-01	-0.3399

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Breast		IDC: Invasive ductal carcinoma
		DCIS: Ductal carcinoma in situ
		Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:00085445	Breast	Precancer	epidermis development	35/1080	324/18723	2.71e-04	3.96e-03	35
GO:00099136	Breast	Precancer	epidermal cell differentiation	23/1080	202/18723	1.43e-03	1.50e-02	23
GO:00302163	Breast	Precancer	keratinocyte differentiation	17/1080	139/18723	2.71e-03	2.39e-02	17
GO:00605374	Breast	Precancer	muscle tissue development	37/1080	403/18723	3.60e-03	2.98e-02	37
GO:00020649	Breast	Precancer	epithelial cell development	23/1080	220/18723	4.28e-03	3.35e-02	23
GO:00147063	Breast	Precancer	striated muscle tissue development	35/1080	384/18723	5.10e-03	3.83e-02	35
GO:006053711	Breast	IDC	muscle tissue development	50/1434	403/18723	4.91e-04	6.45e-03	50
GO:000854412	Breast	IDC	epidermis development	41/1434	324/18723	1.03e-03	1.14e-02	41
GO:000991312	Breast	IDC	epidermal cell differentiation	28/1434	202/18723	1.62e-03	1.60e-02	28
GO:00147061	Breast	IDC	striated muscle tissue development	46/1434	384/18723	1.67e-03	1.63e-02	46
GO:00302161	Breast	IDC	keratinocyte differentiation	21/1434	139/18723	2.06e-03	1.95e-02	21
GO:00343414	Breast	IDC	response to interferon-gamma	21/1434	141/18723	2.46e-03	2.22e-02	21
GO:00435883	Breast	IDC	skin development	33/1434	263/18723	3.46e-03	2.87e-02	33
GO:000206414	Breast	IDC	epithelial cell development	28/1434	220/18723	5.53e-03	4.05e-02	28
GO:00075172	Breast	IDC	muscle organ development	38/1434	327/18723	6.63e-03	4.62e-02	38
GO:006053721	Breast	DCIS	muscle tissue development	50/1390	403/18723	2.39e-04	3.74e-03	50
GO:00147062	Breast	DCIS	striated muscle tissue development	46/1390	384/18723	8.88e-04	1.01e-02	46
GO:000854422	Breast	DCIS	epidermis development	40/1390	324/18723	1.05e-03	1.16e-02	40
GO:000991322	Breast	DCIS	epidermal cell differentiation	27/1390	202/18723	2.11e-03	1.97e-02	27
GO:00302162	Breast	DCIS	keratinocyte differentiation	20/1390	139/18723	3.24e-03	2.74e-02	20

Page: 1 2 3 4 5 6 7 8 9 10

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0513218	Breast	Precancer	Salmonella infection	49/684	249/8465	2.92e-09	6.15e-08	4.71e-08	49
hsa0520514	Breast	Precancer	Proteoglycans in cancer	30/684	205/8465	1.00e-03	7.18e-03	5.50e-03	30
hsa0513219	Breast	Precancer	Salmonella infection	49/684	249/8465	2.92e-09	6.15e-08	4.71e-08	49
hsa0520515	Breast	Precancer	Proteoglycans in cancer	30/684	205/8465	1.00e-03	7.18e-03	5.50e-03	30
hsa0513224	Breast	IDC	Salmonella infection	55/867	249/8465	2.07e-08	4.49e-07	3.36e-07	55
hsa0520523	Breast	IDC	Proteoglycans in cancer	42/867	205/8465	7.69e-06	9.99e-05	7.48e-05	42
hsa045109	Breast	IDC	Focal adhesion	32/867	203/8465	8.60e-03	4.23e-02	3.17e-02	32
hsa0513234	Breast	IDC	Salmonella infection	55/867	249/8465	2.07e-08	4.49e-07	3.36e-07	55
hsa0520533	Breast	IDC	Proteoglycans in cancer	42/867	205/8465	7.69e-06	9.99e-05	7.48e-05	42
hsa0451013	Breast	IDC	Focal adhesion	32/867	203/8465	8.60e-03	4.23e-02	3.17e-02	32
hsa0513243	Breast	DCIS	Salmonella infection	55/846	249/8465	8.71e-09	1.87e-07	1.38e-07	55
hsa0520542	Breast	DCIS	Proteoglycans in cancer	39/846	205/8465	5.36e-05	5.58e-04	4.11e-04	39
hsa0513253	Breast	DCIS	Salmonella infection	55/846	249/8465	8.71e-09	1.87e-07	1.38e-07	55
hsa0520552	Breast	DCIS	Proteoglycans in cancer	39/846	205/8465	5.36e-05	5.58e-04	4.11e-04	39
hsa0513220	Cervix	CC	Salmonella infection	74/1267	249/8465	1.33e-09	2.54e-08	1.50e-08	74
hsa0520516	Cervix	CC	Proteoglycans in cancer	60/1267	205/8465	9.13e-08	1.18e-06	7.00e-07	60
hsa0451010	Cervix	CC	Focal adhesion	59/1267	203/8465	1.53e-07	1.84e-06	1.09e-06	59
hsa040109	Cervix	CC	MAPK signaling pathway	62/1267	302/8465	4.89e-03	1.67e-02	9.86e-03	62
hsa05132110	Cervix	CC	Salmonella infection	74/1267	249/8465	1.33e-09	2.54e-08	1.50e-08	74
hsa0520517	Cervix	CC	Proteoglycans in cancer	60/1267	205/8465	9.13e-08	1.18e-06	7.00e-07	60

Page: 1 2 3 4 5 6 7

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

FLNB

SNV

Missense_Mutation

novel

c.1132G>A

p.Asp378Asn

p.D378N

O75369

protein_coding

deleterious(0.03)

probably_damaging(0.924)

TCGA-5L-AAT1-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

letrozol

FLNB

SNV

Missense_Mutation

novel

c.1797N>T

p.Gln599His

p.Q599H

O75369

protein_coding

deleterious(0.01)

possibly_damaging(0.726)

TCGA-A2-A25A-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unspecific

Cytoxan

FLNB

SNV

Missense_Mutation

c.1202N>A

p.Thr401Asn

p.T401N

O75369

protein_coding

deleterious(0.02)

benign(0.03)

TCGA-A7-A26J-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

FLNB

SNV

Missense_Mutation

rs144158201

c.2035N>T

p.Pro679Ser

p.P679S

O75369

protein_coding

tolerated(0.15)

benign(0.314)

TCGA-A8-A08F-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

5-fluorouracil

FLNB

SNV

Missense_Mutation

rs768998920

c.163N>C

p.Glu55Gln

p.E55Q

O75369

protein_coding

deleterious(0)

probably_damaging(0.98)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

FLNB

SNV

Missense_Mutation

c.2166G>C

p.Trp722Cys

p.W722C

O75369

protein_coding

tolerated(0.1)

probably_damaging(0.997)

TCGA-AR-A0TS-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

FLNB

SNV

Missense_Mutation

rs80356520

c.4912C>G

p.Arg1638Gly

p.R1638G

O75369

protein_coding

deleterious(0.02)

possibly_damaging(0.726)

TCGA-AR-A1AP-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

FLNB

SNV

Missense_Mutation

novel

c.6208N>T

p.Val2070Leu

p.V2070L

O75369

protein_coding

deleterious(0.01)

possibly_damaging(0.626)

TCGA-AR-A24M-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Hormone Therapy

tamoxiphen

FLNB

SNV

Missense_Mutation

novel

c.3056N>T

p.Thr1019Ile

p.T1019I

O75369

protein_coding

deleterious(0.02)

possibly_damaging(0.673)

TCGA-BH-A0HF-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

arimidex

FLNB

SNV

Missense_Mutation

rs142229998

c.7462N>A

p.Gly2488Ser

p.G2488S

O75369

protein_coding

deleterious(0.02)

probably_damaging(0.926)

TCGA-BH-A208-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1